Prekallikein and kallikrein inhibitor in liver cirrhosis and hepatitis.
Plasma prekallikrein (kallikreinogen) and kallikrein inhibitor, assayed with the kaolin activable esterase method, have been evaluated in 20 patients with hepatic cirrhosis, in 12 cases with jaundice from acute viral hepatitis, and in 9 normal. A significant reduction of the plasma prekallikrein in cirrhosis has been found. A lowering of plasma prekallikrein has also been observed in viral hepatitis; in this condition, however, the modifications were less important than those obtained in cirrhosis. In three cases of hepatitis, the behaviour of the plasma prekallikrein and kallikrein inhibitor have been controlled during the period of the disease and compared with the behaviour of some conventional parameters, such as serum transaminases and bilirubin. An important increase of the prekallikrein level has been observed during the improvement of hepatitis. These data confirm the implication of the prekallikrein-kallikrein system in severe liver diseases, and indirectly points out the role of the liver in maintaining the physiological balance of the kallikrein system.
D000328:Adult; D000368:Aged; D007611:Aprotinin / Q000097:blood*; D001120:Arginine / Q000378:metabolism; D004789:Enzyme Activation; D006506:Hepatitis A / Q000097:blood*; D006801:Humans; D007610:Kallikreins / Q000097:blood* / Q000378:metabolism; D007616:Kaolin / Q000494:pharmacology; D008103:Liver Cirrhosis / Q000097:blood*; D008875:Middle Aged; D011288:Prekallikrein / Q000097:blood*
D007616:Kaolin; D011288:Prekallikrein; D007611:Aprotinin; D001120:Arginine; D007610:Kallikreins